The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells

Cancer Letters

Volumn 268, Issue 1, 2008, Pages 46-55

  Jane, Esther P ^a   Pollack, Ian F ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

17 AAG; Akt; Apoptosis; Enzastaurin; Glioma; GSK3 ; PKC

Indexed keywords

BISINDOLYLMALEIMIDE; CASPASE 3; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYTOCHROME C; ENZASTAURIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN; LIPOCORTIN 5; PROTEIN BAX; PROTEIN KINASE B; TANESPIMYCIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

APOPTOSIS; BENZOQUINONES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYTOCHROMES C; DOWN-REGULATION; DRUG SYNERGISM; GLIOMA; HSP90 HEAT-SHOCK PROTEINS; HUMANS; INDOLES; LACTAMS, MACROCYCLIC; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION;

EID: 48149106913     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.039     Document Type: Article

References (40)

1. Couldwell W.T., Uhm J.H., Antel J.P., and Yong V.W. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery 29 (1991) 880-886 (Discussion 886-887)
2. Premkumar D.R., Arnold B., Jane E.P., and Pollack I.F. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells. Mol. Carcinog. 45 (2006) 47-59
3. Baltuch G.H., and Yong V.W. Signal transduction for proliferation of glioma cells in vitro occurs predominantly through a protein kinase C-mediated pathway. Brain Res. 710 (1996) 143-149
4. von Deimling A., Louis D.N., and Wiestler O.D. Molecular pathways in the formation of gliomas. Glia 15 (1995) 328-338
5. da Rocha A.B., Mans D.R., Regner A., and Schwartsmann G. Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?. Oncologist 7 (2002) 17-33
6. Goekjian P.G., and Jirousek M.R. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs 10 (2001) 2117-2140
7. Balendran A., Hare G.R., Kieloch A., Williams M.R., and Alessi D.R. Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484 (2000) 217-223
8. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
9. Aeder S.E., Martin P.M., Soh J.W., and Hussaini I.M. PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 23 (2004) 9062-9069
10. Kawakami Y., Nishimoto H., Kitaura J., Maeda-Yamamoto M., Kato R.M., Littman D.R., Leitges M., Rawlings D.J., and Kawakami T. Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J. Biol. Chem. 279 (2004) 47720-47725
11. Partovian C., and Simons M. Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Calpha in endothelial cells. Cell Signal. 16 (2004) 951-957
12. Fang X., Yu S., Tanyi J.L., Lu Y., Woodgett J.R., and Mills G.B. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol. Cell. Biol. 22 (2002) 2099-2110
13. Goode N., Hughes K., Woodgett J.R., and Parker P.J. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J. Biol. Chem. 267 (1992) 16878-16882
14. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., and Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378 (1995) 785-789
15. Graff J.R., McNulty A.M., Hanna K.R., Konicek B.W., Lynch R.L., Bailey S.N., Banks C., Capen A., Goode R., Lewis J.E., Sams L., Huss K.L., Campbell R.M., Iversen P.W., Neubauer B.L., Brown T.J., Musib L., Geeganage S., and Thornton D. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65 (2005) 7462-7469
16. Carducci M.A., Musib L., Kies M.S., Pili R., Truong M., Brahmer J.R., Cole P., Sullivan R., Riddle J., Schmidt J., Enas N., Sinha V., Thornton D.E., and Herbst R.S. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24 (2006) 4092-4099
17. Herbst R.S. Targeted therapy using novel agents in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 3 Suppl 1 (2002) S30-S38
18. Premkumar D.R., Arnold B., and Pollack I.F. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol. Carcinog. 45 (2006) 288-301
19. Clarke P.A., Hostein I., Banerji U., Stefano F.D., Maloney A., Walton M., Judson I., and Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19 (2000) 4125-4133
20. Hostein I., Robertson D., DiStefano F., Workman P., and Clarke P.A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 61 (2001) 4003-4009
21. Munster P.N., Marchion D.C., Basso A.D., and Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. 62 (2002) 3132-3137
22. Fujita N., Sato S., Ishida A., and Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 277 (2002) 10346-10353
23. Sato S., Fujita N., and Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 97 (2000) 10832-10837
24. Basso A.D., Solit D.B., Munster P.N., and Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21 (2002) 1159-1166
25. Xu W., Mimnaugh E., Rosser M.F., Nicchitta C., Marcu M., Yarden Y., and Neckers L. Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 276 (2001) 3702-3708
26. Riss T.L., and Moravec R.A. Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays. Assay Drug Dev. Technol. 2 (2004) 51-62
27. Jane E.P., Premkumar D.R., and Pollack I.F. AG490 influences UCN-01-induced cytotoxicity in glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation. Cancer Lett. 257 (2007) 36-46
28. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
29. Kamada S., Kikkawa U., Tsujimoto Y., and Hunter T. Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). J. Biol. Chem. 280 (2005) 857-860
30. Moreau A.S., Jia X., Ngo H.T., Leleu X., O'Sullivan G., Alsayed Y., Leontovich A., Podar K., Kutok J., Daley J., Lazo-Kallanian S., Hatjiharissi E., Raab M.S., Xu L., Treon S.P., Hideshima T., Anderson K.C., and Ghobrial I.M. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 109 (2007) 4964-4972
31. Podar K., Raab M.S., Zhang J., McMillin D., Breitkreutz I., Tai Y.T., Lin B.K., Munshi N., Hideshima T., Chauhan D., and Anderson K.C. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 109 (2007) 1669-1677
32. Querfeld C., Rizvi M.A., Kuzel T.M., Guitart J., Rademaker A., Sabharwal S.S., Krett N.L., and Rosen S.T. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J. Invest. Dermatol. 126 (2006) 1641-1647
33. Tabatabai G., Frank B., Wick A., Lemke D., von Kurthy G., Obermuller U., Heckl S., Christ G., Weller M., and Wick W. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann. Neurol. 61 (2007) 153-161
34. Hurbin A., Coll J.L., Dubrez-Daloz L., Mari B., Auberger P., Brambilla C., and Favrot M.C. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells. J. Biol. Chem. 280 (2005) 19757-19767
35. McJilton M.A., Van Sikes C., Wescott G.G., Wu D., Foreman T.L., Gregory C.W., Weidner D.A., Harris Ford O., Morgan Lasater A., Mohler J.L., and Terrian D.M. Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 22 (2003) 7958-7968
36. Okhrimenko H., Lu W., Xiang C., Hamburger N., Kazimirsky G., and Brodie C. Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res. 65 (2005) 7301-7309
37. Sansal I., and Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 22 (2004) 2954-2963
38. Joseph B., Marchetti P., Formstecher P., Kroemer G., Lewensohn R., and Zhivotovsky B. Mitochondrial dysfunction is an essential step for killing of non-small cell lung carcinomas resistant to conventional treatment. Oncogene 21 (2002) 65-77
39. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., and Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
40. Joza N., Susin S.A., Daugas E., Stanford W.L., Cho S.K., Li C.Y., Sasaki T., Elia A.J., Cheng H.Y., Ravagnan L., Ferri K.F., Zamzami N., Wakeham A., Hakem R., Yoshida H., Kong Y.Y., Mak T.W., Zuniga-Pflucker J.C., Kroemer G., and Penninger J.M. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 410 (2001) 549-554